Cargando…

P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES

Detalles Bibliográficos
Autores principales:	KHOO, C. M., SONG, X., WU, Q., COX, G. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430101/ http://dx.doi.org/10.1097/01.HS9.0000846172.64321.0a

Ejemplares similares

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
por: Weitz, Ilene Ceil
Publicado: (2023)

P791: COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR EXTRAVASCULAR HAEMOLYSIS
por: Baral, A. J., et al.
Publicado: (2022)

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
por: Peffault de Latour, Régis, et al.
Publicado: (2023)

PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
por: Catania, Federica, et al.
Publicado: (2023)

Characteristics of Taiwanese patients of PNH in the international PNH registry
por: Chou, Wen-Chien, et al.
Publicado: (2016)

IMMUNE LYSIS OF NORMAL HUMAN AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELLS : III. THE MEMBRANE DEFECTS CAUSED BY COMPLEMENT LYSIS
por: Rosse, Wendell F., et al.
Publicado: (1966)

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
por: Bodó, Imre, et al.
Publicado: (2023)

Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.
por: Price, M. R., et al.
Publicado: (1982)

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
por: Meyer, Saskia, et al.
Publicado: (2014)

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
por: Gulati, Sunita, et al.
Publicado: (2019)

Can Urinary Complement Proteins Stratify Patients to Therapeutic Complement Inhibitors?
por: Medjeral-Thomas, Nicholas R.
Publicado: (2022)

In vivo inhibition of the antibody response by a complement receptor- specific monoclonal antibody
Publicado: (1990)

Clinical Frailty Scale and the FRAIL checklist: Can they complement each other?
por: Cheung, Emmanuel Hei-Lok, et al.
Publicado: (2023)

In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats
Publicado: (1994)

Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
por: Zelek, Wioleta M., et al.
Publicado: (2020)

Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement
por: Hao, Yuwan, et al.
Publicado: (2014)

Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis
por: Li, Lin-Lin, et al.
Publicado: (2019)

Can complement fix placental malaria?
por: Doritchamou, Justin Y. A., et al.
Publicado: (2021)

Arthrogenicity of type II collagen monoclonal antibodies associated with complement activation and antigen affinity
por: Koobkokkruad, Thongchai, et al.
Publicado: (2011)

Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage
por: Nagamachi, Seiji, et al.
Publicado: (2014)

CCENT exam cram: (exam 640-822)
por: Valentine, Michael, et al.
Publicado: (2008)

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy
por: Khanani, Arshad M., et al.
Publicado: (2022)

Complement receptor is an inhibitor of the complement cascade
Publicado: (1981)

Antibody-independent complement activation by myelin via the classical complement pathway
Publicado: (1982)

S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: Scheinberg, Phillip, et al.
Publicado: (2023)

Complement
por: Treffers, Henry P.
Publicado: (1966)

Complement Factor I Variants in Complement-Mediated Renal Diseases
por: Zhang, Yuzhou, et al.
Publicado: (2022)

Activation of mouse peritoneal macrophages by monoclonal antibodies to Mac-1 (complement receptor type 3)
Publicado: (1987)

Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody
Publicado: (1983)

A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN
por: Hoekstra, Hedzer, et al.
Publicado: (2017)

Monoclonal antibodies effectively potentiate complement activation and phagocytosis of Staphylococcus epidermidis in neonatal human plasma
por: de Vor, Lisanne, et al.
Publicado: (2022)

Neuropilin-1 Acts as a Receptor for Complement Split Products
por: Battin, Claire, et al.
Publicado: (2019)

Can Cell Bound Complement Activation Products Predict Inherited Complement Deficiency in Systemic Lupus Erythematosus?
por: Raj, Naveen, et al.
Publicado: (2016)

A complementary new drug for PNH
por: Brodsky, Robert A.
Publicado: (2020)

Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022)

Complement and Complement Targeting Therapies in Glomerular Diseases
por: Andrighetto, Sofia, et al.
Publicado: (2019)

Viral interference with antibody and complement
por: Lubinski, John, et al.
Publicado: (1998)

Vinculin Y822 is an important determinant of ligand binding
por: DeWane, Gillian, et al.
Publicado: (2023)

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
por: Röth, Alexander, et al.
Publicado: (2023)

P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tj2itq14gkursd84v8kofog5mh